Non-alcoholic Fatty Liver Disease (NAFLD)
Drug Market
Non-alcoholic Fatty Liver Disease (NAFLD) Drug
Market Scope: Industry Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Non-alcoholic Fatty Liver Disease (NAFLD) Drug
Market Size and Growth
The global Non-alcoholic Fatty Liver Disease (NAFLD) Drug market is projected to experience significant growth due to increasing prevalence of NAFLD and rising awareness about its treatment. Market size is expected to reach $XX billion by 2025, driven by high demand for effective pharmaceutical interventions. Key players in the market include XYZ Pharmaceuticals and ABC Therapeutics.
Request Sample Report
Companies Covered (Covid 19 Impact Covered)
◍ Conatus Pharmaceuticals
◍ Daewoong Pharmaceutical
◍ Galmed International
◍ Kyorin Pharmaceutical
◍ Metabolic Solutions Development
◍ Novartis AG
◍ Phenex Pharmaceuticals
◍ Raptor Pharmaceuticals
◍ TCM Biotech International
◍ Tobira Therapeutics
◍ Verva Pharmaceuticals
◍ Zafgen
The nonalcoholic fatty liver disease (NAFLD) drug market is highly competitive with key players such as Novartis AG, Tobira Therapeutics, and Conatus Pharmaceuticals. These companies focus on developing innovative therapies and conducting clinical trials to address the unmet medical needs of patients with NAFLD, contributing to the market growth.
- Novartis AG: $48.66 billion (2020)
- Tobira Therapeutics: Acquired by Allergan for up to $1.695 billion
- Conatus Pharmaceuticals: $6.2 million (2020)
Request Sample Report
Market Segmentation
By Application
◍ Application I
◍ Application II
By Product
◍ Type I
◍ Type II
Request Sample Report
$ X Billion USD
Market Growth
Request Sample Report
THANK YOU Email : sales@reportprime.com USA : +1 507 500 7209 Website : https://www.reportprime.com/ Request Sample Report Contact US Our Clients